Vaxcyte, INC Form 4 insider transactions

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on September 18, 2024, according to a Form 4 filing with the SEC.

Director Teri Loxam exercised stock options and sold Vaxcyte shares under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan, while also transferring shares due to a divorce settlement.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, CFO of Vaxcyte, Inc., reports disposition of shares to cover tax obligations upon vesting of restricted stock units.

Vaxcyte's CEO, Grant Pickering, reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., exercised stock options and sold shares to cover tax obligations, according to a Form 4 filing.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reported the exercise of stock options and sale of common stock on September 3, 2024, according to a Form 4 filing with the SEC.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Andrew Guggenhime, CFO of Vaxcyte, Inc., exercised stock options and sold shares under a pre-arranged trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, sold a portion of his common stock holdings on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte CEO Grant Pickering sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CFO, Andrew Guggenhime, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan on July 18, 2024.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., exercised stock options and sold 5,000 shares of common stock at $85 per share on July 16, 2024, under a pre-arranged 10b5-1 trading plan.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., reports the sale of 5,000 shares of common stock at $80 per share on July 8, 2024, following the exercise of stock options.

Director John Furey acquired 16,760 stock options in Vaxcyte, Inc. on July 2, 2024.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reported the exercise of stock options and subsequent sale of common stock on July 1, 2024, according to a Form 4 filing with the SEC.

Vaxcyte's Chief Operating Officer, Jim Wassil, executed multiple sales of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares on June 18, 2024, according to a Form 4 filing with the SEC.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports the disposition of 335 common stock shares to cover tax withholding obligations.

Director Jacks Lee reports acquisition of 1,550 shares of common stock and 7,250 stock options in Vaxcyte, Inc.